

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Peraza Lisa</u>  (Last) (First) (Middle) 4242 CAMPUS POINT COURT SUITE 200  (Street) SAN DIEGO CA 92121  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/13/2020	3. Issuer Name and Ticker or Trading Symbol <u>HERON THERAPEUTICS, INC. /DE/ [ HRTX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) _____ <u>VP, Chief Accounting Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11,259	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (Right to Buy)	(1)	03/31/2024	Common Stock	35,000	13.91	D	
Employee Stock Option (Right to Buy)	(1)	12/12/2024	Common Stock	17,417	9.05	D	
Employee Stock Option (Right to Buy)	(1)	12/22/2025	Common Stock	20,000	29.41	D	
Employee Stock Option (Right to Buy)	(1)	10/07/2026	Common Stock	20,000	16.83	D	
Employee Stock Option (Right to Buy)	(2)	12/21/2026	Common Stock	27,500	13	D	
Employee Stock Option (Right to Buy)	(2)	02/13/2027	Common Stock	25,000	13.85	D	
Employee Stock Option (Right to Buy)	(2)	12/18/2027	Common Stock	27,500	17	D	
Employee Stock Option (Right to Buy)	(2)	12/15/2028	Common Stock	20,160	24.97	D	
Employee Stock Option (Right to Buy)	(2)	12/19/2029	Common Stock	26,400	25.02	D	

**Explanation of Responses:**

- 1. The stock option is fully vested and exercisable.
- 2. The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.

**Remarks:**

/s/ Lisa Peraza

10/15/2020

\*\* Signature of Reporting  
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**